Prolaris Biopsy Test Shows Strong Prognostic Performance in 8,000+ Patient Meta-Analysis
MYGN sits 71% above its 52-week low of $3.53.
Summary
A new large-scale meta-analysis, pooling data from 14 studies and over 8,000 patients, demonstrates the strong prognostic performance of Myriad Genetics' Prolaris Biopsy Test for localized prostate cancer. Published in Clinical Genitourinary Cancer, the findings show Prolaris adds significant insight beyond conventional clinical risk categories, aiding in treatment decisions and active surveillance. This robust clinical validation is a significant positive for Myriad, especially following its reported wider net loss in Q1 2026, as it strengthens the commercial case for a key diagnostic product and can drive increased adoption and reimbursement.
At the time of this announcement, MYGN was trading at $6.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $566.7M. The 52-week trading range was $3.53 to $8.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.